| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910298267903321 |
|
|
Titolo |
Endocannabinoids / / edited by Roger G. Pertwee |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed. 2015.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (477 p.) |
|
|
|
|
|
|
Collana |
|
Handbook of Experimental Pharmacology, , 0171-2004 ; ; 231 |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Pharmacology |
Cytology |
Neurosciences |
Psychopharmacology |
Immunology |
Cytokines |
Growth factors |
Pharmacology/Toxicology |
Cell Biology |
Cytokines and Growth Factors |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references at the end of each chapters and index. |
|
|
|
|
|
|
|
|
Nota di contenuto |
|
Preface; The Endocannabinoid System: A Look Back and Ahead; Contents; Endocannabinoids and Their Pharmacological Actions; 1 Introduction; 2 Evidence That Certain Endogenous Compounds Target Cannabinoid Receptors Orthosterically; 2.1 Evidence from Binding Assays; 2.2 Evidence from Two Functional Bioassays; 2.2.1 [35S]GTPgammaS Binding Assay; 2.2.2 Cyclic AMP Assay; 3 Non-Cannabinoid Receptors and Channels Targeted by Endogenous Cannabinoid Receptor Ligands at Submicromolar Concentrations; 3.1 Non-Cannabinoid G Protein-Coupled Receptors; 3.1.1 GPR55; 3.2 Ligand-Gated Ion Channels |
3.2.1 5-HT3 Receptors3.2.2 Nicotinic Acetylcholine Receptors; 3.2.3 Glycine Receptors; 3.2.4 Ionotropic Glutamate NMDA Receptors; 3.3 Transient Receptor Potential Channels; 3.3.1 TRPV1; 3.3.2 TRPM8 |
|
|
|
|
|
|
|
|
|
|
|
Channels; 3.4 Voltage-Gated Calcium Channels; 3.4.1 T-Type Cav3 Calcium Channels; 3.5 Potassium Channels; 3.5.1 ATP-Sensitive Inward Rectifier KATP Channels of the 2TM Domain Family; 3.5.2 Voltage-Gated Kv and KCa Channels of the 6TM Domain Family; 4 Allosteric Endocannabinoids; 5 Conclusions; References; Biosynthesis and Fate of Endocannabinoids |
1 Endocannabinoids and Endocannabinoid-Like Compounds2 Biosynthesis of the Endocannabinoids; 3 Uptake of the Endocannabinoids: Proposed Mechanisms; 4 Degradation of the Endocannabinoids; 4.1 FAAH and NAAA; 4.2 MGL, ABHD6 and ABHD12; 5 Conclusions; References; Distribution of the Endocannabinoid System in the Central Nervous System; 1 Introduction; 1.1 Overview; 1.2 Cells Expressing Components of the ECS; 1.3 Subcellular Localization of CB1 Cannabinoid Receptors; 2 Retina; 2.1 Receptors; 2.2 Synthetic Enzymes; 2.3 Degradative Enzymes; 3 Cerebral Cortex; 3.1 Neocortex; 3.1.1 Receptors |
3.1.2 Synthetic Enzymes3.1.3 Degradative Enzymes; 3.2 Olfactory Areas (Olfactory Bulb, Piriform Cortex, Associated Regions); 3.2.1 Receptors; 3.2.2 Synthetic Enzymes; 3.2.3 Degradative Enzymes; 3.3 Hippocampal Formation; 3.3.1 Receptors; 3.3.2 Synthetic Enzymes; 3.3.3 Degradative Enzymes; 3.4 Cortical Subplate (Other Amygdala Nuclei); 3.4.1 Receptors; 3.4.2 Synthetic Enzymes; 3.4.3 Degradative Enzymes; 4 Subcortical Nuclei (Striatum, Basal Ganglia); 4.1 Striatum (Dorsal, Caudate); 4.1.1 Receptors; 4.1.2 Synthetic Enzymes; 4.1.3 Degradative Enzymes; 4.2 Striatum (Ventral, Accumbens) |
4.2.1 Receptors4.2.2 Synthetic Enzymes; 4.2.3 Degradative Enzymes; 4.3 Striatum Medial (Lateral Septum, Septohippocampal, etc.); 4.3.1 Receptors; 4.3.2 Synthetic Enzymes; 4.3.3 Degradative Enzymes; 4.4 Striatum Caudal (Striatum-like Amygdala Nuclei, Central Amygdala, Bed Nucleus, Medial Amygdala, Etc.); 4.4.1 Receptors; 5 Cerebellum and Associated Nuclei; 5.1 Cerebellar Cortex; 5.1.1 Receptors; 5.1.2 Synthetic Enzymes; 5.1.3 Degradative Enzymes; 5.2 Deep Cerebellar Nuclei (Fastigial, Interpos, Dentate Nucleus); 5.2.1 Receptors; 5.2.2 Synthetic Enzymes; 5.2.3 Degradative Enzymes; 6 Brainstem |
6.1 Diencephalon |
|
|
|
|
|
|
Sommario/riassunto |
|
There is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced “autoprotection”, for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced “autoimpairment”. This volume describes the physiology, pathophysiology and pharmacology of the endocannabinoid system and potential strategies for targeting this system in the clinic. |
|
|
|
|
|
|
|
| |